dc.contributor.author
Ratia, Carlos
dc.contributor.author
Cepas, Virginio
dc.contributor.author
Soengas, Raquel
dc.contributor.author
Navarro, Yolanda
dc.contributor.author
Velasco de Andrés, María
dc.contributor.author
Iglesias, Maria José
dc.contributor.author
Lozano Soto, Francisco
dc.contributor.author
López Ortiz, Fernando
dc.contributor.author
Soto, Sara M.
dc.date.issued
2022-11-21T16:30:53Z
dc.date.issued
2022-11-21T16:30:53Z
dc.date.issued
2022-03-03
dc.date.issued
2022-11-21T16:30:53Z
dc.identifier
https://hdl.handle.net/2445/191021
dc.description.abstract
The worldwide emergence and spread of infections caused by multidrug-resistant bacteria endangers the efficacy of current antibiotics in the clinical setting. The lack of new antibiotics in the pipeline points to the need of developing new strategies. Recently, gold-based drugs are being repurposed for antibacterial applications. Among them, gold(III) complexes have received increasing attention as metal-based anticancer agents. However, reports on their antibacterial activity are scarce due to stability issues. The present work demonstrates the antibacterial activity of the gold(III) complex 2 stabilized as C∧S-cycloaurated containing a diphenylphosphinothioic amide moiety, showing minimum inhibitory concentration (MIC) values that ranged from 4 to 8 and from 16 to 32 mg/L among Gram-positive and Gram-negative multidrug-resistant (MDR) pathogens, respectively. Complex 2 has a biofilm inhibitory activity of only two to four times than its MIC. We also describe for the first time a potent antibacterial synergistic effect of a gold(III) complex combined with colistin, showing a bactericidal effect in less than 2 h; confirming the role of the outer membrane as a permeability barrier. Complex 2 shows a low rate of internalization in Staphylococcus aureus and Acinetobacter baumannii; it does not interact with replication enzymes or efflux pumps, causes ultrastructural damages in both membrane and cytoplasmic levels, and permeabilizes the bacterial membrane. Unlike control antibiotics, complex 2 did not generate resistant mutants in 30-day sequential cultures. We detected lower cytotoxicity in a non-tumoral THLE-2 cell line (IC50 = 25.5 μM) and no acute toxicity signs in vivo after an i.v. 1-mg/kg dose. The characterization presented here reassures the potential of complex 2 as a new chemical class of antimicrobial agents.
dc.format
application/pdf
dc.publisher
Frontiers Media
dc.relation
Reproducció del document publicat a: https://doi.org/10.3389/fmicb.2022.815622
dc.relation
Frontiers in Microbiology, 2022, vol. 13
dc.relation
https://doi.org/10.3389/fmicb.2022.815622
dc.rights
cc-by (c) Ratia, Carlos et al., 2022
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Biomedicina)
dc.subject
Resistència als medicaments
dc.subject
Medicaments antibacterians
dc.subject
Drug resistance
dc.subject
Antibacterial agents
dc.title
A C˄S-cyclometallated gold(III) complex as novel antibacterial candidate against drug-resistant bacteria
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion